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INTRODUCTION 
 Diabetes is the leading cause of end stage renal disease throughout the world.  
Diabetic nephropathy occurs in 25-30% of type 1 diabetes. Increased albumin 
excretion rate has been considered the first clinical sign of diabetic nephropathy both 
in type1 and type2 diabetes(1). Though microalbuminuria is considered as the early 
marker of diabetic nephropathy, in some patients decrease in glomerular filtration rate 
and hypertension may precede(2).  It has been proved that patients with 
normoalbuminuria and decreased gfr in type 2 and type 1 diabetic patients had 
significant glomerular changes in renal histopathology and also has been proved that 
these patients had rapid progression of diabetic renal disease(3).  As albuminuria is 
not a predictor but a marker of diabetic nephropathy lot of researches had been 
undertaken to identify  early predictor such as hyperfiltration, estimation of early gfr 
decline with both creatinine and cystatin c, plasma and urinary markers of 
inflammatory, oxidative pathways and fibrotic pathways as well as genetic variants 
that predispose patients to the onset and progression of diabetic nephropathy. 
Mogensen etal proposed the natural  history of diabetic nephropathy in type1 diabetic 
patients. Accordingly stage1 is characterised by  hyperfiltration and hypertrophy of 
glomeruli, stage 2 – basement membrane thickening and mesangial expansion, stage  
3 – microalbuminuria ( incipient nephropathy), stage 4- macroalbuminuria and 
decline in gfr (overt nephropathy), stage 5- end stage renal disease. This traditional 
view of the natural history of diabetic kidney disease is now challenged. It is clear that 
patients spontaneously regress from microalbuminuria and even overt nephropathy 
levels of proteinuria to normal levels of proteinuria and some patients never develop 
proteinuria at all prior to progressing on to decreasing gfr  and end stage kidney 
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disease. So the true value of albuminuria is questioned. The existence of 
normoalbuminuric diabetic kidney disease was demonstrated in the  united kingdom 
prospective diabetes study ( UKPDS).  A landmark study by perkins and krolewski 
showed that in 400 patients in  joslin diabetes center with type1 diabetes were more 
likely to regress in their albuminuria than to go on and progress to nephropathy. They 
followed them for a baseline level of 2 years showing that they had persistent  
microalbuminuria for those 2 years, and then they followed them for an additional 6 
years, and they averaged  their albuminuria levels at 2 year intervals. At years 2,4, and 
6 about 40% exhibited regression, all spontaneously whereas only 7-15% progressed 
on to nephropathy. Those who were younger , hemoglobin A1c less than 8%, systolic 
blood pressure of less than 115 and lower total cholesterol and triglycerides were 
more likely to regress.  
 Hovind etal at the steno diabetes center looked at patients with diabetes and 
nephrotic range of proteinuria  and followed them for an average of 5-6 years and 
found that among 126 patients 22% remitted spontaneously. They also pointed out 
that younger patients, those with  low mean arterial blood pressure and low serum 
cholesterol  were those who had spontaneous regression 
 There are also reports saying that even typical nodular sclerosis can  reverse 
following strict  euglycemia as of following pancreatic transplant for type1 diabetes in 
a period of upto 10 years(5).  
 So, there is non proteinuric diabetic kidney disease and Proteinuric Diabetic 
kidney disease can also spontaneously regress(4).  So both the positive and negative 
predictive values of proteinuria have been challenged. 
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 This was also demonstrated in animal models many years back in cohen 
diabetic sensitive and diabetic resistant rats. In this study such animals were  fed with 
diabetic diet and found that diabetic sensitive rat developed fall in gfr without 
proteinuria and they had typical diabetic histological changes. 
 So non proteinuric diabetic nephropathy should also be looked for instead of 
focusing only on proteinuria for detecting early diabetic nephropathy. 
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AIM OF THE STUDY 
 
1. To confirm the existence of normoalbuminuric diabetic nephropathy in                          
type1 diabetics    
     2..   To  study the  characteristics of these patients 
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REVIEW OF LITERATURE 
 Diabetic nephropathy is a clinical syndrome characterized by persistent 
albuminuria (>300 mg/24 hours) (also referred to as macroalbuminuria or 
proteinuria), a steady decline in glomerular filtration rate (GFR), and elevated blood 
pressure (6). Two third of patients with diabetic nephropathy develop renal failure 
requiring either dialysis or renal transplantation.  Diabetic nephropathy is the most 
common cause of chronic renal failure in india and accounts for more than one third 
of patients enrolled in long-term dialysis programs. Patients with nephropathy 
frequently develop other complications, in particular cardiovascular disease including 
hypertension and stroke, resulting in increased risk of early mortality .  In patients 
with type 1 diabetes, 40 years after onset of the disease, the mortality rate is 90% for 
those patients with nephropathy but only 30% for those patients without renal disease 
(7). Thirty percent of diabetic patients die as a result of renal failure .  Thus, renal 
complications of diabetes are important, and glomerulosclerosis and vascular disease 
are the most important causes of renal failure in the diabetic patient. 
 There are two main forms or types of diabetes, classified as type 1 and type  
2 .  . Type 1 diabetes encompasses the vast majority of cases that are primarily due to 
pancreatic β- cell destruction.  The form named type 2 diabetes includes the most 
prevalent form of the disease, which results from insulin resistance with an insulin 
secretory defect.  Type 1 diabetes accounts for 5 to 10% of people with diabetes and 
type 2 diabetes affects approximately 90% of those with the disease . The natural 
history, pathologic features, and pathogenesis of diabetic nephropathy are remarkably 
similar but not identical in patients with type 1 and type 2 diabetes.           
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Clinical Presentation 
Frequency and Risk Factors 
Incidence and Prevalence 
 Several studies from the 1980s showed a cumulative incidence of diabetic 
nephropathy of 25% to 40% after 25 years of type 1 diabetes with a declining trend in 
cumulative incidence compared with those patients diagnosed in the 1930s and in the 
1950s.  A study from Sweden published in 1994 reported a dramatic decline in the 
cumulative incidence of diabetic nephropathy in patients diagnosed before age  
15 years (8). The investigators showed that the cumulative incidence of diabetic 
nephropathy after 25 years declined from 28% in those patients with an onset of type 
1 diabetes between 1961 and 1965 compared with 8.9% in those patients with an 
onset between 1966 and 1970 and 5.8% in a cohort from 1971 to 1975.  The patients 
with persistent albuminuria had higher mean glycosylated hemoglobin levels than did 
those without albuminuria.  Furthermore, in all patients, the average glycosylated 
hemoglobin value decreased between 1980 and 1989.  Most follow-up studies 
confirmed the declining trend of incidence of diabetic nephropathy in patients with 
type 1 diabetes (9,10).  Some investigators have not found such a decline in incidence 
of diabetic nephropathy .  Recent data reveal cumulative incidence of 13% to 16% of 
diabetic nephropathy in patients with type 1 diabetes 20 years after the onset of 
diabetes.  The peak annual incidence of developing proteinuria in type 1 diabetes is 
approximately 3% between 10 and 20 years of diabetes duration (11,12).  The 
prevalence of proteinuria in patients with type 1 diabetes is between 15% and 40% 
(11,13,14). 
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 The prevalence and cumulative incidence of proteinuria (as a measure of 
diabetic nephropathy) in patients with type 2 diabetes is comparable but not identical 
with those of type 1 diabetes .  The higher variability in the prevalence of proteinuria 
(2% to 20%) in patients with type 2 diabetes is, in part, due to ethnic differences in 
the prevalence of diabetic nephropathy.  No evidence of declining cumulative 
incidence of diabetic nephropathy with increasing calendar year of diabetes onset (as 
demonstrated in some studies in patients with type 1 diabetes) has been demonstrated 
in a study of European White type 2 diabetic patients . 
Duration of Disease 
 The incidence of diabetic glomerulosclerosis increase with the duration of 
diabetes.  This correlation was shown most clearly by Andersent et al. in a large 
cohort study from Steno Memorial Hospital.  These authors studied 1475 patients 
with type 1 diabetes for 25 or more years  until death.  These investigators found an 
increase in the annual incidence of renal disease through the first 16 years after 
diagnosis of diabetes with a decline in the number of patients developing renal lesions 
after that period.  Only 4% of patients developed nephropathy after 35 years of 
diabetes.  Rudberg et al  in a study of adolescents with type 1 diabetes with a mean 
duration of disease of 10.9 years, found that duration of disease was an important 
factor in overall severity of glomerulopathy. Overt nephropathy caused by 
glomerulosclerosis first appears 10 to 15 years after the onset of type 1 diabetes and 
after 5 to 10 years in patients with type 2 diabetes  (15).  Although diabetic 
nephropathy is rare before 10 years of diabetes duration in patients with type 1 
diabetes, approximately 3% of patients with newly diagnosed type 2 diabetes have 
evidence of diabetic nephropathy .  Because the biologic onset and duration of type 2 
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diabetes is often uncertain and therefore, the biologic onset and clinical 
onset/diagnosis might be years apart, the course of diabetic nephropathy in this patient 
population is less well defined than in patients with type 1 diabetes.  In addition, the 
more frequent co morbidities in patients with type 2 diabetes, such as hypertension 
and cardiovascular diseases, may alter the clinical presentation of nephropathy in 
patients with type 2 diabetes. 
Gender 
 In earlier studies, more females have been reported to be affected than males 
(16). Another study demonstrated a clear predominance of males compared with 
females. More recent data show only a slight male predominance with a male-to-
female incidence ratio of end-stage renal disease (ESRD) from diabetic nephropathy 
of 1.1:1.  However, the finding that girls and women are diagnosed with diabetes at a 
rate of 1.5 times that of boys and men indicates that men are at greater risk of 
developing renal disease in diabetes than are women. 
Racial and Ethnic Factors 
 Several distinct racial and ethnic groups have a greater incidence of type  
2 diabetes than do other such groups.  Nephropathy is also more common in the 
diabetic populations of various ethnic and racial groups.  The prevalence of diabetic 
nephropathy is highest in Native Americans, followed by African Americans, 
Hispanics and Caucasians .  The Pima Indians of the South Western United states 
have the highest prevalence of type 2 diabetes .  Fully half of all Pimas develop type  
2 diabetes by the time they have reached 35 years of age.  A cumulative incidence rate 
of proteinuria as high as 50% has been reported in the Pima Indians 20 years after the 
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diagnosis of diabetes . African Americans also have a higher incidence both of 
diabetes and of the associated diabetic nephropathy. Increased prevalence of diabetic 
nephropathy is also noted in Hispanic Americans .  These differences in prevalence of 
diabetic nephropathy among ethnic groups are present after adjustment for other risk 
factors such as hypertension, socioeconomic status, age, and prevalence of diabetes 
within the population . Asians and West Indians tend to developy type 2 diabetes at an 
earlier age, and in these patients diabetic nephropathy more often leads to renal failure 
and death . 
Genetic Factors 
 Several lines of evidence support an important role for various genetic factors 
in the development of diabetic nephropathy.  The fact that diabetic nephropathy 
develops only in a subset of patients with diabetes has long been interpreted as 
evidence pointing to genetic factors in the pathogenesis.  Familial clustering of 
diabetic nephropathy in both type 1 and type 2 diabetes is another indication for 
probable genetic predisposition for the disease .  Seaquist et al  studied two sets of 
families with type 1 diabetes.  In the first group, the probands had normal renal 
function, whereas in the second group, the probands had undergone renal 
transplantation necessitated by end-stage diabetic nephropathy. Two of 12 siblings in 
the first set of families developed diabetic nephropathy.  However, 24 of 29 siblings 
of probands with previously documented nephropathy later developed nephropathy 
themselves.  The only predictive factor of the later evolution of diabetic nephropathy 
was the presence of renal disease in the proband.  No difference was noted between 
the two groups with regard to duration of diabetes, blood pressure, or glycosylated 
hemoglobin (a measure of glycemic control).  Although a common environmental 
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factor is not excluded, the investigators believed that heredity plays a role in 
determining the susceptibility to diabetic nephropathy.  A study from the Joslin Clinic 
(Boston, MA) examined the development of diabetic nephropathy in families with 
multiple siblings with type 1 diabetes . The cumulative incidence for overt proteinuria 
in siblings of patients with advanced diabetic nephropathy was 71.5%  after 25 years 
compared with 25.4% in siblings of patients without persistent proteinuria.  The 
authors of this study pointed out that this risk difference of 46.1% was sufficiently 
large to suggest that the genetic event is important and may signal a dominantly 
inherited gene.  A genome scan in families with type 1 diabetes for linkage for 
diabetic nephropathy identified a linkage to a region that contains the angiotensin II 
type 1 receptor gene (17).   In addition, several metabolic pathways and genes have 
also been proposed as candidates for genetic include the following : 
1. Genes that mediate the synthesis and degradation of the glomerular capillary 
basement membrane and mesangial matrix components. 
2. Components of blood pressure regulation and the renin-angiotensin system. 
3. various cytokines, growth factors, signaling molecules and transcription 
factors. 
4. advanced glycation processes. 
5. genes that mediate glucose metabolism and transport.      
 A recent comprehensive study analyzing 115 candidate genes using a novel 
approach of transmission/disequilibrium test in patients with type 1 diabetes identified 
20 genes with polymorphism (18).  According to the investigators, at lease some of 
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these genes may have influence on the risk of diabetic nephropathy.  However, inspite 
of a large number of studies that tested the association of candidate genes with 
diabetic nephropathy, the findings are mostly inconclusive and the genetic 
determinants of diabetic nephropathy are not yet fully understood. 
Smoking 
 Cigarette smoking is a well-established independent risk factor for the 
development of the microvascular complications of diabetes.  There are also date 
indicating that cigarette smoking contributes to the development of diabetic 
nephropathy.  Cigarette smoking increase urinary albumin excretion (UAE) in 
patients with type 1 diabetes and also in type 2 diabetes .  In addition, smoking 
cessation is associated with reduced UAE in patients with type 1 diabetes . However, 
as to whether smoking has a significant impact on renal functional deterioration in 
type 1 diabetic patients is some what controversial.  Although several studies showed 
an association between cigarette smoking an progressive nephropathy in patients with 
type 1 diabetes, a recent large prospective observational cohort study  failed to 
demonstrate an association between smoking status and the rate of decline in GFR 
with and without ACE inhibitor therapy. 
Clinical Presentation 
Clinical Stages 
 Mogensen et al (19) described five clinical stages in the evolution of diabetic 
glomerulosclerosis in patients with type 1 diabetes.  stage I is characterized by the 
presence of both hyperfunction, as manifested by increased glomerular filtration rate 
(GFR), and hypertrophy, as recognized by enlargement of the kidneys affecting both 
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glomeruli and tubules.   Stage II develops silently over many years in some patients 
and is marked by the evolution of glomerular lesions in the absence of clinical 
evidence of renal disease.  In particular, the glomerular basement membrane (GBM) 
begins to thicken and the mesangial matrix expands (20).  A correlation exists 
between elevation of glycosylated hemoglobin and increased GFR at this stage .  
Stage III marks incipient diabetic nephropathy.  It is recognized by the occurrence of 
microalbuminuria, which is defined as ranging between 20 and 200 µg/min (30 to 300 
mg/day) on repeated measurements (21). Renal function is preserved as determined 
by blood urea nitrogen (BUN) and serum creatinine.  Typically, this stage is 
associated with intermittent proteinuria with slowly increasing urinary albumin 
excretion over all years .  Once UAE attains levels of 0.075 to 0.1 g/day, the patient 
has sustained significant renal damage and clinical nephropathy is likely to occur .  
Increased blood pressure may be present at this stage, but it rarely occurs in patients 
with UAE less than 100 mg/day (22). Stage IV is characterized by the presence of 
overt diabetic nephropathy as clinically manifested by proteinuria >300mg/day and a 
declining GFR.  The nephrotic syndrome has been reported in 6% of patients with 
overt nephropathy .  Microscopic hematuria may be identified in 28% to 48% of 
patients with diabetic nephropathy (21). This stage is usually associated with rising 
systemic blood pressure and the presence of other diabetic complications.  
Development of overt nephropathy with albuminuria was once considered to be the 
“point of no return” with steady progression to ESRD.  Aggressive antihypertensive 
treatment showed beneficial effects on the progression of diabetic nephropathy in 
both type 1 and type 2 diabetic patients .  Stage V is the appearance of ESRD as a 
direct result of diabetic nephropathy. 
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Microalbuminuria and Risk for Diabetic Nephropathy 
 Based on values of albuminuria, the preclinical phases of diabetic nephropathy 
consist of normoalbuminuric and microalbuminuric stages.  Approximately 70% of 
screened patients with type 1 and type 2 diabetes have normoalbuminuria. 
Microalbuminuria, defied as 30 to 299 mg/24 hours, a cutoff value adopted by the 
Ameircan Diabetes Association (23,24), is widely regarded as the best available 
marker for risk of later development of diabetic nephropathy in both type 1 and type 2 
diabetic patients. Microalbuminuria is considered to be a promoter of renal functional 
deterioration, and a reduction of microalbuminuria or prevention of development of 
microalbuminuria is important in preserving renal function.   
 According to several studies, the prevalence of Microalbuminuria is less than 
20% in patients with type 1 diabetes, and on average, slightly greater than 20% in 
patients  with type 2 diabetes.  
 The rate of progression from microalbuminuria to proteinuria over 5 to 10 
years in patients with type 1 diabetes is approximately 15% to 30% . The estimated 
incidence of progression from normoalbuminuria to microalbuminuria and subsequent 
proteinuria during a follow-up of 6 to 9 years in patients with type 2 diabetes is 
approximately 20% to 30% . A recent European study using data from more than 
5000 patients with type 2 diabetes found that progression from normoalbuminuria to 
microalbuminuria occurred at a rate of 2.0% per year and from microalbuminuria to 
proteinuria at 2.8% per year . 
 Vibertia et al  studied 87 patients with type 1 diabetes with follow-up of at 
least 14 years in 63 patients. These patients were divided in to two groups depending 
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on their UAE.Seven of the 8 patients with UAE rate (but still within the definition of 
microalbuminuria) developed proteinuria greater than 0.5g/day at follow-up, whereas 
only 2 to 55 patients in the low-UAE group had proteinuria at that time. The risk of 
developing clinical nephropathy was  24 times greater in the high-excretion 
group.Futhermore,38% had died at follow-up ,whereas only 9% were dead in the low-
UAE group. These findings were confirmed by several follow-up studies .  Warram et 
al  determined UAE by albumin-to-creatinine ratio and found that 6% of patients with 
type1 diabetes for 1 to 3 years had microalbuminuria. At 10 years ,this prevalence had 
increased to 20% and to 52% at 20 years. After 30 years, the prevalence of overt 
nephropathy was 27%.The finding suggests that some of the 52% with 
microalbuminuria at 20 years did not progress to overt renal disease, whereas those 
with microalbuminuria in the first 10 years almost always progressed to overt 
nephropathy. These authors also determined that the median transition time from 
microalbuminuria to overt nephropathy is 9 years.However,not all patients with 
microalbuminuria early in the course of type 1 diabetes progress to overt nephropathy, 
as indicated in a study by Shield et al . 
 Also, in a significant proportion of patients with type 1 or type 2 diabetes, 
microalbuminuria can revert to normoalbuminuria. In a large European study, a 
regression rate of 50.6% has been demonstrated in type 1 diabetics with 
microalbuminuria after 7 years of follow-up(25). In the Steno-2 study,46 (31%) of 
151 patients with type 2 diabetes and microalbuminuria reverted to normoalbuminuria 
during 7.8 years of follow-up(26). Antihypertensive therapy and improved glycemic 
control were independent predictors for remission(26). 
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End Stage Renal Disease(ESRD) in Diabetics 
 End-stage renal disease usually occurs 3 to 20 years after the onset of 
persistent proteinuria .  Once overt proteinuria occurs, progression to ESRD seems to 
be inevitable despite good metabolic control.  Patients who have type 1 diabetes and 
proteinuria develop ESRD more often than those who have type 2 diabetes and 
proteinuria .The cumulative incidence of ESRD is 50% in patients with type 1 
diabetes 10 years after the onset of proteinuria (8) compared with 3% to 11% in 
proteinuric type 2 diabetes patients .  However, because of the higher prevalence of 
type2 diabetes, 80% or more patients with ESRD secondary to diabetes have type 2 
diabetes. The incidence of ESRD is also higher in women, reflecting the 
demographics of diabetes and diabetic nephropathy in the general population. 
Although there are considerable differences between various countries in the 
prevalence of ESRD among diabetics, a trend of increasing prevalence of ESRD in 
the population has been noted in all countries over the last 10 years. 
Natural History and Progression of Diabetic Nephropathy 
 The natural history of diabetic nephropathy in patient with type 1 diabetes is 
well characterized showing various but steady decline in GFR ranging from 1 to 
24mL/minute−1/year−1 (mean 12 mL/minutes−1/ year−1) and a concomitant rise in 
alubuminuria and in arterial blood pressure. 
 Although the great majority of patients with diabetic nephropathy have type 2 
diabetes, there are far fewer studies and date available on the natural progression of 
diabetic nephropathy in patients with type 2 diabetes .  In 1996,Nelson et al  published 
the first study on the natural course of kidney function in patients with type 2 diabetes 
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in pima Indian followed for 4 years. The GFR was elevated at  the onset of type  
2 diabetes, remained elevated while normal albumin excretion or microalbuminuria 
persisted, and declined progressively after the development of macroalbuminuria, The 
average decline in GFR was 11mL/minute/year. Higher renal plasma flow, 
alubuminuria and body-mass index predicted a more rapid decline in GFR,Whereas 
blood pressure and HbA1C did not. IN a study from Steno Diabetes Center from 
Denmark,12 normotensive or borderline hypertensive male patients  with type  
2 diabetes were followed for 55 months .  No treatment for hypertension was 
implemented, and the low average rate of decline in GFR (4.5mL/Minutes/Year)was 
similar to that seen in normotensive patients with type 1 diabetes. No significant 
correlation between putative progression promoters , such a blood pressure values, 
alubuminuria, or hyperglycemia, and the rate of decline of GFR were identified. This 
study indicated that the progression of diabetic nephropathy in normotensive 
untreated patients with type 2 diabetes is slow. 
 Plugh et al  compared the course of ESRD in patients with type 1 diabetes and 
those with type 2 diabetes. These investigators found that hyperglycemia was more 
prominent in the patients with type 1 diabetes and renal disease, whereas hypertension 
was more frequently seen in the patients with type 2 diabetes and renal disease. In 
agreement with other studies, they found that the course to ESRD was shorter in 
patients with type 2 diabetes. They also noted that patients with type 1 diabetes more 
frequently suffered from other microvascular complications such as retinopathy or 
neuropathy, whereas patients with type 2 diabetes more often have myocardial 
infarcts or congestive heart failure. 
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Progression Factors and Renoprotection 
 Because only 30% to 40% of diabetics develop diabetic nephropathy, and the 
occurrence of such lesions decreases life expectancy, it is important to determine 
predictors of nephropathy as well as means to delay or prevent the progression of this 
disease. Several factors including onset of type 1 diabetes later in life, parental type  
1 diabetes, edema, and an abnormal electrocardiogram independently predict 
progression of renal disease in diabetes. However, the most important factors include 
hypertension and the degree of metabolic control. 
Blood Pressure Control   
 The high prevalence of hypertension in patients with type 1 diabetes (40%) 
and type 2 diabetes (70%), even before the onset of microalbuminuria, is well 
established (27). The impact of hypertension on the progression of diabetic 
nephropathy is also well documented .Ravid et al(28)  followed 195 patients with type 
2 diabetes with normal blood pressure at the outset of the study for 14 years and 
examined the relationship between their blood pressure and the progression of renal 
disease. The investigators found that the patients who became hypertensive showed 
and increased propensity for developing proteinuria(60.0% compared with 20.8% in 
the normotensive group) despite similar degree of metabolic control. Furthermore, 
among the patients who developed proteinuria, the hypertensive patients showed a 
greater decline in the GFR .Parving et al  examined the effect of long-term 
antihypertensive therapy on progression of diabetic renal disease compared with the 
natural history of the disease. These investigators studied 45 patients with type 1 
diabetes and nephropathy for a median follow-up of 16 years. The cumulative death 
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rate was 45% 16 years after the onset of diabetic nephropathy compared with 94% 
recorded by Krolewski et al.  The latter study was an examination of the natural 
history of the disease without antihypertensive therapy. 
 There is strong association between blood pressure. Increase in alubuminuria 
and the rate of decline in glomerular filtration rate (GFR) in both type 1 and type 2 
diabetic patients . Early studies showed that long-term antihypertensive treatment in 
type 1 diabetic patients with nephropathy reduces alubuminuria and the rate of decline 
of GFR This finding has been confirmed by several follow-up studies.  Treatment of 
hypertension also significantly reduces the risk of development of microalbuminuria. 
In patients with type 2 diabetes, a reduction of systolic blood pressure form 154 to 
144 mm Hg reduced the risk of the development of microalbuminuria by 29%. 
Effective control of hypertension has also been shown to slow the rate of progression 
to renal failure even in patients with overt nephropathy.   Sawicki et al compared 
patients with long-term diabetes who received either routine antihypertensive therapy 
or intensive treatment for hypertension. The patients were followed for a mean of 68 
months. Four percent of the patients in the intensive-treatment group died compared 
with 28% in the routine-treatment group. Renal replacement therapy was required in 
only 9% of the patients in the intensive-therapy group compared with 23% in the 
routine-treatment group, and progression of renal disease occurred in 27% of the 
intensively treated group compared with 59% of the other group. 
 Antihypertensive treatment not only slows down the rate  of decline of GFR 
but in comes patients, may lead to regression of the disease(i.e.,delta 
GFR(upto1mL/Minute/year) equal to the natural aging process).In a study of 10 type 
1 diabetic patients with nephropathy, Pravin et al  showed slowing of the rate of 
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decline in GFR from 0.91mL/minute/month in a period of 29 months before 
aggressive antihypertensive treatment to a rate of 0.39 mL/minute/month during an 
interval of 39 months of aggressive antihypertensive therapy. This change was also 
accompanied by a decline in urinary albumin excretion (UAE).No difference was seen 
in degree of metabolic control during the two period of investigation. 
 Higher blood pressures, even in the range considered normal, are predictive of 
diabetic nephropathy risk. Patients with advanced diabetic  nephropathy and type 1 
diabetes had higher mean arterial blood pressure during adolescence .  The risk of 
developing nephropathy is also enhanced in diabetic patients with a family history of 
hypertension.  Krolewski et al  studied 89 patients approximately 20 years after the 
onset of type 1 diabetes. Thirty- three of these patients had nephropathy at follow-up. 
The risk of nephropathy was tripled for those patients having a parent with 
hypertension. Furthermore, the patients with nephropathy had higher maximal 
velocity of lithium-sodium countertransport in red cells, a marker of risk for essential 
hypertension. The risk  of developing nephropathy was increased still more in those 
patients with a history of poor metabolic control in their first 10 years of the disease. 
The authors of this study concluded that the risk of renal disease in diabetics is 
increased in patients with a genetic predisposition to hypertension, with a  further 
increment in the risk resulting for poor metabolic control. 
 In addition to its beneficial effects on the rate of progression of diabetic 
nephropathy, aggressive blood pressure lowering therapy also significantly extends 
the median survival of diabetic patients with persistent proteinuria. Early studies 
showed an average survival of patients with persistent proteinuria owing to diabetic 
nephropathy of 5 to 7 years , the renal prognosis is similar in patients with proteinuria 
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who have type1 or type 2 diabetes .  A significantly improved median survival time of 
14 years or greater has been documented in patients treated with aggressive 
antihypertensive therapy .  Data from the Framingham and Multiple Risk Factor 
Intervention Trial Diabetic Cohort showed that cardiovascular mortality was 
increased by a factor of two to four in diabetic patients, and there was  clear 
association between systolic blood pressure and complications without any threshold 
value.  
Glycemic Control 
 Studies beginning in 1982 indicated that microalbuminuria in diabetic patients 
is a good predictor of the later development of diabetic nephropathy and decline in 
renal function.  Several groups showed that the extent of UAE correlates with the 
degree of Glycemic control in both type 1 diabetes  and type 2 diabetes. This finding 
led investigators to examine the effect of strict metabolic control during the stage of 
incipient nephropathy on the later development of overt glomerulosclerosis. The 
importance of degree of metabolic control in the progression of diabetic renal disease 
is illustrated in the study of Krolewki et al from the Joslin Clinic .  These investigators 
found that the degree of Glycemic control in the first 20 years of type 1 diabetes  was 
a strong predictor of ESRD. The prevalence of ESRD was 36.3% in patients with the 
worst control compared with 14.4% with better control and only 9.2% in those with 
the best control. Stephenson et al  found similar results in Europe in a study of 3250 
patients with type 1 diabetes. 
 Bangstad et al   performed a prospective study of patients with type 1 diabetes 
and microalbuminuria in two groups randomized to conventional treatment or to 
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continuous subcutaneous insulin infusion. Renal biopsies were taken at the beginning 
of the study and again between 26 and 34 months later. The investigators found that 
strict metabolic control was established in the infusion-treated group as determined by 
mean glycosylated hemoglobin levels. The GBM thickness increased in each group, 
but the increment of GBM change was larger in the conventional therapy group. 
Volume fraction of mesangial matrix was increased only in the conventional-therapy 
group. The investigators concluded that a close relationship was present between the 
level of blood glucose and the characteristic changes of early diabetic nephropathy.  
 Meta-analysis of several randomized studies   comparing the effects of long-
term intensive versus conventional blood glucose control on the risk of nephropathy 
progression in normoalbuminuric (80%) and microalbuminuric type 1 diabetic 
patients showed beneficial effects on the progression from normoalbuminuria to 
microalbuminuria by intensive treatment. Intensified Glycemic control in Diabetes 
Control and Complication study did not decrease the rate of progression to 
macroalbuminuria in patients  with type 1 diabetes who were microalbuminuric at the 
beginning of the study. Strict Glycemic control in patients who were 
normoalbuminuric at the beginning of the study did, however reduce the occurrence 
of microalbuminuria by 39% and that of alubuminuria by 54% at the end of 6.5-year 
study. Also, improved Glycemic control reduced the renal functional deterioration in 
proteinuric with type 1 diabetes in another study. 
 Only a few studies analyzed the effects of glycemic control on the rate of 
progression of nephropathy in patients with type 2 diabetes. The progression rate of 
microalbuminuria to macroalbuminuria was reduced with intensive glycemic control  
in a Japanese study.  Progressive beneficial effects of intensive metabolic control have 
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also been found by the U.K. Prospective Diabetes Study on the development of 
microalbuminuria and overt proteinuria. However, Several studies failed to 
demonstrate a significant correlation between Glycemic control and progression of 
GFR in albuminuric patients with type 2 diabetes. 
 It is now generally accepted that the degree of glycemic control is an 
extremely important factor in the development and evaluation of diabetic 
nephropathy. The impact of hyperglycemia on progression of diabetic nephropathy 
has been well documented ,especially during the later stages of the disease, once 
albuminuria has developed. The  impact of hyperglycemia during the later stages of 
the disease once albuminuria has developed, is debated. 
Blockage of the Renin-Angiotensin System 
 Blockage of the rennin-angiotensin system with angio-tensin-converting 
enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB) confers additional 
benefit on preserving renal function. The first large  study of these agents was 
reported by Lewis et al,  who examined the effect of captropril in a randomized 
controlled study of 409 patients with type 1 diabetes with a median follow up of 3 
years. These investigators found that doubling of the serum creatinine occurred in 43 
of the patients taking the placebo but in only 25 patients who received captropril. The 
risk of death, or the need for either dialysis or renal transplantation, was reduced by 
half in the captropril treatment group. These investigators concluded that captropril 
slowed the progression of diabetic nephropathy more effectively that simple control 
of blood pressure. Ravid et al  examined 94 patients with type 2 diabetes, serum 
creatinine below 1.4mg/dL., and microalbuminuria between 30 and 300 mg/24 hours. 
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The patients were assigned to treatment with enalapril for 5 years or placebo. Each 
subject then had a choice of receiving enalapril  or receiving no therapy for 7 years 
had stable microalbuminuria during the period. The untreated group showed an 
increase in microalbuminuria from 123 to 310 mg/24 hours in 5 years, with an 
additional increase to 393 mg/24 hours in the last 2 years of the study.The treated 
patients showed no change in the reciprocal of the serum creatinine . those who did 
not receive any therapy showed a decline of 13% in  5years and 16 % at 7 
years.Treatment resulted in an absolute risk reduction of 42%. Discontinuation of 
therapy renewed progression of the renal disease. Six of the 33 patients (18%) who 
received treatment throughout the 7 year period progressed to macroalbuminuria, 
compared with 12 of 20 patients (60%) who were not treated with enalapril. Mean 
blood pressure was maintained at 108mm Hg or less in all patients. 
 The findings of three randomized, placebo-controlled studies in type 1 and 
type 2 normotensive and normoalbuminuric diabetic patients have suggested 
beneficial effects on the development of microalbuminuria .   A meta analysis of 12 
trials  evaluating 698 nonhypertensive microalbuminuric patients with type 1 diabetes 
treated with ACE Inhibitors also showed decrease of the risk of progression to 
proteinuria by 60% and increase of the chances to revert to normoalbuminuria. It has 
been documented that in type 2 diabetic patients with hypertension and 
normoalbuminuria, the renoprotective effects of blood pressure reduction were similar 
in those treated with ACE inhibitors versus calcium antagonist , or beta blockade . 
Type 2 diabetic patients with microalbuminuria also benefit from treatment with ACE 
inhibitors In a double-blind randomized study, type 2 diabetic patients with 
microalbuminuria and normal blood pressure were receiving enalapril or placebo for 5 
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years. The renal function remained stable and only 12% of patient in the study group 
developed diabetic nephropathy. In contrast, the renal function in the placebo-treated 
group declined by 13% and 42% of patients in this group developed nephropathy. The 
short-term renoprotective effects of ACE inhibitors were similar to those of ARBs in 
reducing the albuminuria in patients with type 2 diabetes.  In the MICRO-
HOPE(Heart Outcomes Prevention Evaluation) study , the ACE inhibitor ramipril 
decreased the risk of overt nephropathy by 24% and the risk of cardiovascular death 
in patients with type 2 diabetes who were older than 55 years of age with one 
additional cardiovascular risk factor by 37%. The effect of these agents are complex 
but include alternations in glomerular hemodynamics resulting in decrease of 
hyperfiltration, inhibition of glomerular and tubular hypertrophy, and lowering of 
systemic blood pressure. 
Effects of Treatment on Progression of Nephropathy 
 Additional evidence of the importance of various risk factors or predictors in 
the progression of nephropathy can be garnered from studies in which therapy is 
aimed at modifying these factors. Restricting dietary protein has been used as a mean 
to reduce glomerular hyperfiltration . Zellar et al (29) found that dietary protein and 
phosphorus restriction resulted in a slowing of progression of renal disease 
independent of blood pressure and glycemic control that was comparable in the two 
experimental groups. 
Pathologic Findings 
 The possible association of specific glomerular lesions with diabetes mellitus 
was first recognized by Kimmelstiel and Wilson in 1936 (30). They described a series 
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of eight patients who, autopsy, had a striking formation of nodules. Seven of these 
patients had diabetes, whereas the remaining patient with moribund without available 
clinical history. Edema and heavy proteinuria were present, accompanied by high 
blood pressure in some patients. At the same time, Murakami  in Japan described a 
similar histologic picture in a single patient. Additional studies since that time have 
described the histologic alterations that are characteristic of diabetic 
glomerulosclerosis and are accompanied by a stereotypical clinical course. The 
clinical significance of this disease has engendered a large body of work examining 
pathogenesis and maneuvers to alter the course of the disease. 
Gross Appearance 
 The kidney of the diabetic patient may be increased, decreased, or normal in 
size. At early stages, it is invariably increased, particularly in patients with 
hyperfiltration. When diabetic glomerulosclerosis progresses with scarring and loss of 
nephrons, one sees a reduction in the size of kidney, but the end-stage kidney of the 
diabetic patient does not commonly show gross contraction.  On cut surface, 
preservation of normal architecture is noted. With proper lighting, one may be able to 
detect hypertrophied glomeruli within the cortex. Frequently, the arteries at the 
corticomedullary junction are prominent because thickening of their walls resulting 
from arteriosclerosis prevents their walls resulting from arteriosclerosis prevents their 
retraction into the parenchyma. The main renal artery and it branches may show 
atherosclerosis. 
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Light Microscopic Findings 
Glomeruli 
 The glomeruli show a constellation of findings. These include a diffuse form 
with mesangial sclerosis manifested as an increase in mesangial matrix and uniform 
thickening of capillary walls, a nodular lesion sometimes combined with 
microaneurysms, exudative or hyalinosis lesions, and the capsular drop. At early 
stages, glomerular volume is enlarged 70% as compared with glomeruli of 
nondiabetic subjects .  Filtration surface area increased by 80% in a similar 
comparison.  
Diffuse Lesion. 
 The diffuse lesion consists of widespread increase in eosinophilic, periodic 
acid-Schiff(PAS)- positive material within the mesangium as first described by 
Spuhler and Zollinger.  Hypercellularity  is uncommon , although it may occur. 
Uniform increase in the thickness of the capillary walls may be seen. The increase in 
glomerular basement membrane(GBM) thickness may be seen as early as 2 years after 
the onset of diabetes mellitus, and it is not usually accompanied by clinical evidence 
of renal dysfunction . The mesangial alterations progress in severity .  Capillary walls 
continue to thicken at the same time, increasing with duration of disease .  The GBM 
is thickened and mesangial volume and matrix volume fraction are increased by the 
time microalbuminuria appears clinically .  The combination of mesangial expansion 
and thickened GBM Results in decreasing patency of capillary Lumina and decreased 
filtration surface area. As the glomeruli become obsolete, they do not shrink to the 
degree seen in other diseases affecting glomeruli resulting in solidified glomeruli. 
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However, one can find typical ischemic change in certain of the glomeruli because 
arteriosclerosis contributes to the evolution of diabetic renal disease. Bowman’s 
capsule may be thickened in the more advance lesions. Advanced glycosylation end 
products(AGEs) are believed to play a role in the pathogenesis of the lesions in 
diabetic nephropathy. Such AGEs have been identified in the expanded mesangium of 
diabetic patients, but have not been seen in control specimens. 
Nodular Lesion  
 The nodular lesion is the type of change first recognized by Kimmelstiel and 
Wilson(30). Typically, it is characterized by the accumulation of homogeneous 
eosinophilic material within the mesangium, often appearing as a rounded 
accentuation of the mesangial expansion observed in the diffuse form or diabetic 
glomerulosclerosis . Formation of Kimmelstiel- Wilson nodule is recognized when 
expansion of the mesangium attains a size at least one and  one-half times that of the 
normal mesangial stalk.  As such, it should measure more than 40µm in diameter, but 
it may be up to 100 µm. Such lesions are usually acellular although nuclei may be 
arranged at the periphery. Blood worth noted at least one nodule in 25% of kidneys 
studied in 200 consecutive autopsies of patients with diabetes mellitus. Several 
lobules may be affected within any given glomerular tuft, and in this case, the nodules  
often vary in size  On occasion, glomeruli may have a single large nodule. These 
variants tend to have a laminated appearance, particularly when viewed with silver or 
reticulin stains they may have a separate pathogenesis.  The number of glomeruli 
affected varies from case to case. The nodules are PAS-positive, the smaller lesions 
staining more intensely than the larger ones. They stain green with Masson’s 
trichrome, blue with Mallory’s stain, and black with silver stains. Falk et al reported 
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an increase in mesangial staining for fibronectin, laminin, and type IV  and V collagen 
in early and moderately advanced mesangial lesions with an increase only of type V 
collagen in late nodules. Hennigar et al(31) found that 7.6% of diabetic patients had 
severe nodular lesions, and in their review of the literature discovered a range of 27% 
to 46%  of diabetic patients with nodular lesions. 
 Two populations of nodular lesions exist. The smaller, more numerous 
nodules arise as continued mesangial expansion of the diffuse lesion .  However, the 
larger, often solitary and laminated variants may originate in relation to 
microaneurysms  which are defined in the context as cystic dilatations of the capillary 
measuring more than 35µm  in diameter . Investigators have observed that the 
frequency of microaneurysms and large nodules in similar(9% to 25% of diabetic 
kidneys.  Furthermore, microaneurysms may arise in association with mesangiolysis , 
and a progression of changes has been described wherein the GBM is  loosened from 
its anchoring points as it reflects back over the mesangium.  This change is 
accompanied  by disintegration of mesangial matrix ,  the appearance of fibrillar  
material, resulting in the formation of several layers and a large module.  Agents 
implicated in the development of microaneurysms include platelet factors, 
hemodynamic factors and possibly changes in elasticity of the GBM . Stout et al  
suggested a different pathogenetic mechanism for the Kimmelstiel Wilson nodule. In 
their hypothesis the first step is the formation of focal mesangiolysis, which 
progresses from an edematous to a proliferative stage characterized by a loose but 
organized fibrillar matrix . As this centralized matrix becomes more condensed, the 
lesion changes from focal nodular mesangial expansion to a simple Kimmelstiel 
Wilson nodule. Repeated injury then results in a similar progression of changes and 
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the eventual formation of the laminated lesion called the complicated nodule. 
Paueksakon et al  combine the idea of repeated microvascular injury with the 
occurrence of mesangiolysis in association with Kimmelstiel Wilson nodules. They 
found increased plasminogen activator inhibitor-1(PAI-1) in such lesions, particularly 
those in which they found fragmented red blood cells, an indicator of microvascular 
injury. 
 Considerable overlap of the diffuse and nodular lesion occurs. However, it  is 
useful to identify the occurrence of the nodular lesion because it signifies a more 
serious pathologic from a diabetic nephropathy  and corresponds well to the presence 
of clinical signs and symptoms. Moreover, the presence of mesangial nodules should 
always arouse suspicion of diabetes. 
Hyalinosis Lesion. 
 The hyalinosis lesion, which is another name for the so-called exudative lesion 
or fibrin cap ,  is often present in diabetic nephropathy. The initial change 
characteristic of this lesion is the accumulation of hynaline eosinophilic homogenous 
material between endothelial cells and the GBM of the capillary loops. As the lesion 
evolves, the material, which represents various plasma constituents, increases in 
amount and eventually occludes the capillary lumen. On occasion, lipid droplets and 
even lipid-laden macrophages may be present within the lesion .  The epithelial cells 
overlying these lesions are frequently enlarged and may show vacuoles or protein 
droplets. Adhesions are often observed between the glomerular lobule containing such 
a lesion and nearby Bowman’s capsule. The material within the capillary lumen stains 
intensely pink with PAS.   Use of the methenamine silver stain with PAS and 
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hematoxylin and eosin counterstains differentiates these lesions from nodules. The 
combination of PAS and eosin intensifies the staining of the hyalinosis lesion, 
producing contrast with the silver-staining nodule. Furthermore, the silver stains the 
basement membrane and reveals the luminal location of the hyalinosis lesion. 
 The lesion is not specific for diabetic nephropathy, although it is seen in 
approximately 60% of diabetic kidneys.  It is identical to the lesion characteristic of 
focal and segmental glomerular sclerosis with hyalinosis and may be seen 
nonspecifically in certain other glomerular diseases including various forms of 
glomerulonephritis and relax nephropathy. The pathogenesis of the lesion is not well 
understood, although its early development has been associated with endothelial 
injury and possible hemodynamic alterations.  Because its  prevalence in diabetic 
kidneys increases with the severity of the nephropathy and correlates with the degree 
of arteriosclerosis, other investigators have suggested that it is  associated with 
ischemia. 
 The lesion called the capsular drop(32) is identified as a round, eosinophilic 
accumulation of material between the basement membrane and parietal  epithelial 
cells of Bowman’s capsule.  It has the same staining qualities as the hyalinosis lesion. 
This unusual lesion is most frequently seen in diabetes, although it may be seen in 
other conditions. 
Miscellaneous Glomerular Changes.  
 One of the early physiologic changes in diabetics is the occurrence of 
glomerular hyperfiltration accompanied by glomerular hypertrophy. Some of these 
patients then proceed to develop the characteristic histologic changes of diabetic 
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nephropathy described earlier, namely increased mesangial matrix,  the nodular 
lesion, increased thickness of the GBM, and the hyalinosis lesion. As these lesions 
evolve, the solidified glomeruli fail to undergo contraction, and the result is a 
population of large obsolescent glomeruli may also emerge in response to the vascular 
disease that is a frequent companion to the glomerular disease in diabetes. Thus, these 
smaller glomeruli are identical to those seen in ischemic renal disease in other 
conditions . Furthermore, they are present in a distribution expected for vascular 
disease; that is they occur in stripes perpendicular to the capsular surface within the 
distribution of the affected vessel. Podocyte injury  may also be seen. Reduction in the 
number of podocytes  has been documented in both type1 and type 2  diabetes .  This 
reduction in podocyte number is associated with increasing proteinuria .  It has been 
further suggested that the loss of podocytes results in denudation of the GBM and 
may be an initiating factor in glomerulosclerosis. 
 Atubular glomeruli has also been seen in diabetic nephropathy(33).Atubular 
glomeruli are defined as those glomeruli that have open glomerular capilaries  but 
have lost their connection to the proximal tubule and presumably do not produce 
filtrate. Accurate determination of these glomeruli requires serial sections. However 
small  glomeruli  surrounded by tissue with marked tubular loss are likely to be 
atubular .Najafian et al,  using the appropriate morphometric  techniques, found that 
17% of glomeruli in diabetics were atubular   and that an additional 51% were 
attached to atrophic tubules. They found that these glomeruli could account for much 
of the variation in glomerular filtration rate in diabetic patients. 
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Tubules 
 The tubules generally show changes that reflect the degree of glomerular 
alterations. Obsolescent glomeruli (of either variety) show atrophy of adjacent tubules 
with decreased size of epithelial cells and diminished luminal diameters. Similar 
changes are also seen in the tubules that belonged to now atubular glomeruli. 
Apoptosis has been detected in both proximal and distal tubules of the diabetic kidney  
and represents a possible mechanism for the loss of the tubular cells. The tubular 
basement membrane is often thicker than expected for the degree of atrophy. 
Occasionally, proximal tubular epithelial cells are finely vacuolated and contain lipid; 
this usually occurs in patients manifesting the nephrotic syndrome. The straight 
portion (S3) of the proximal tubules may show the glycogen-containing Armanni-
Ebstein change, but this is seen only rarely. Tubular basement membranes are 
frequently thickened and may show splitting and lamination. 
Blood Vessels  
 Both arteries and arterioles invariably show the typical changes of 
arteriosclerosis and arteriolosclerosis, respectively. In arteries, this type of injury is 
manifested by varying degrees of intimal thickening accompanied by reduplication of 
elastic lamina. Hyaline arteriolosclerosis is a  frequent  and early manifestation of 
diabetic renal disease and is more pronounced in diabetes that in other diseases of the 
kidney. It is characterized by often striking hyalin deposition in arterioles,  and both 
afferent and efferent limbs may be affected. When this lesion is seen in young people 
, particularly without hypertension, the suspicion of diabetes must be raised. Bohle et 
al  and Osterby et al  noted increase in vascular disease associated with more severe 
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glomerular damage. The presence of intrarenal microaneurysms in arterioles has been 
documented using microangiography . Osterby et al assessed the ration of matrix to 
media in arterioles from diabetic patients with and without microalbuminuria . These 
investigators found that this ratio was increased in patients with microalbuminuria, a 
finding suggesting that arteriolar matrix accumulation may be similar to increased 
matrix elsewhere in diabetes and can occur early in the course of the disease. 
Furthermore, this change progresses with duration of disease . AGEs were identified 
in arteriolar hyalin and in intimal thickening in diabetic patients . Three – dimensional 
analysis of the vascular pole of the glomerulus demonstrated new vessel formation 
with anastomoses between glomerular capillaries near the hilus and peritubular 
capillaries . 
Interstitum 
 Interstitial fibrosis is common in the diabetic kidney and may be accompanied 
by chronic inflammatory infiltrates compose chiefly of T lymphocytes and 
macrophages. The increase in interstitial volume is due largely to increase in cells at 
early stages of diabetic nephropathy associated with only mild  glomerular changes. 
Increase in collagen and other matrix components occur later in the disease. Increased 
fibrosis  of the interstitium is greatest in those cases with arterial and arteriolar 
narrowing; this has been verified by  morphometric  techniques. The presence of 
interstitial fibrosis, particularly when accompanied by inflammatory infiltrate, 
correlates with renal survival. The degree of interstitial fibrosis correlates inversely 
with the GFR . Taft et al  and Bader et al  showed a correlation between increase in 
interstitial fibrosis and final creatinine clearance in patients who had two biopsies. 
Lane et al  demonstrated that mesangial expansion, arteriolar hyalinosis, global 
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glomerular sclerosis, and interstitial expansion are interrelated. However, the 
progression in each compartment is not stereotypical for all patients. Thus, in some 
patients, the severity of interstitial disease may be greater than that of glomerular 
lesions whereas in others, the reverse may be true. 
Immunofluorescence   Microscopy 
 Immunofluorescence techniques have been used in several studies. The typical 
finding is the occurrence of linear staining along the glomerular capillary walls with 
immunoglobulin G (IgG).  The intensity of the staining varies among individual 
patients and does not correspond to the severity of the glomerular lesions.  Linear 
staining of capillary walls has also been reported with IgM, the third component of 
complement(C3), fibrinogen, and albumin.  Staining of the mesangium and 
Kimmelstiel- Wilson nodules is rarer and usually shows fainter staining than that 
reported for capillary walls. 
 Hyalinosis lesions usually stain brightly with IgM and C3, as they do in the 
identical lesions found in focal segmental glomerular sclerosis, phyelonephritis, and 
elsewhere.IgM and C3 are also present in hyaline arteriolosclerosis in diabetes as well 
as in vessels showing hypertensive changes. Hyalinosis lesions may also contain 
fibrinogen and lipoprotein  of fibrinogen, complement ,β-lipoprotein, and small 
amount of IgG. 
 Vessels with hyaline arteriolosclerosis may show similar changes. Linear 
staining for IgG and albumin has also been reported along tubular basement 
membranes and Bowmen’s capsule in patients with advanced diabetic 
glomerulosclerosis .  The staining was thought to reflect structural changes in the 
  35
renal extracellular membranes, which permit entrapment of serum proteins,possibly as 
a result of changes in permeability. It is now thought that advanced glycosylation end 
products may bind to the basement membranes and change their properties. 
Electron Microscopy 
Glomerular Capillary Wall 
 In that capillary wall, morphologic changes are present in both the GBM, 
which is always thickened in most loops, and the epithelial cells, which show variable 
effacement of the foot process.  Most authors agree that this increase in the thickness 
of the GBM is the earliest change .  It should be mentioned that some loops may show 
thinning of the GBM. Huang , using guanidine treatment, showed that the increase in 
basement membrane thickness was due to increased amounts of material from the 
epithelial rather than from the endothelial cells. Changes in the foot processes are 
variable. At times, they remain discrete, whereas other cases have differing degrees of 
effacement. Osteby et al  measured a mean width of the foot process of 352 nm in 
diabetics as compared with a mean width of 224 nm in nondiabetic control patients. 
Other investigators have confirmed this difference in foot process width Widening of 
foot processes appears with the onset of microalbuminuria  and in the more recent 
literature shows a week correlation with the degree of albuminuria.  Pagtalunan et al,  
in a study of Pima Indians, did not document widened foot processes until the stage of 
clinical nephropathy. Furthermore, these investigators noted as absolute loss in the 
number of visceral epithelial cells during clinical nephropathy concurrent with 
mesangial expansion. Thus, the remaining cells had to cover increased surface area. 
These investigators suggested that this podocyte loss may contribute to the 
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progression of diabetic nephropathy. This finding has also been confirmed by other 
investigators. 
 Thickened GBM is always seen in diabetic nephropathy. In fact, a recent study 
has described  the isolated finding of thickened GBM  as a possible manifestation of 
prediabetes or early diabetes in 23 patients who presented with proteinuria greater 
than 0.5g/day sometimes accompanied by hematuria but without clinical evidence of 
diabetes.  Two years later seven patients remained normoglycemic, six had fasting 
blood glucose between 110 and 125mg/dL, three had impaired glucose tolerance, and 
seven had become diabetic .  As duration of diabetes increase, greater variability in 
thickness of the GBM is observed.  In part, this change is related to the thinner GBM 
in microaneurysms ,  but interindividual variation  and interglomerular variation 
contribute to the large standard deviations.  Vogler et al  studied 15 patients with type 
1 diabetes and found areas of attenuation of the GBM  in 6 patients. The thinned areas 
were continuous with the outer aspect of the thickened GBM in sites where the 
membrane has apparent laminations. Mesangiolysis has been described in association 
with the formation of microaneurysms.  Osterby et al   observed similar basement 
membrane thinning in severely affected diabetic kidneys. In such cases, the GBM 
measured as little as 100nm and comprised 1% to 5% of the total capillary length in 
individual glomeruli. The pathogenesis of these alterations in GBM may be related to 
many factors, as discussed more fully beginning in the section on pathogenesis. 
 Changes in the biochemical composition of the GBM have been reported by 
various investigators. Spiro  first recorded such alterations including an increase in 
hydroxylation of lysine and in the number of disaccharide units. Additional work 
form his laboratory has shown decreased heparan sulfate and laminin .  Tamsma et al      
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confirmed the decrease of heparan sulfate and found a correlation between that 
decrease and the degree of proteinuria. Other authors, using immunohistochemical 
localization techniques, detected a change in change density resulting from alteration 
in location of the heparan sulfate rather that a absolute  decrease in the amount  Kim 
et al  showed a change in the chains of collagen type IV in the GBM. 
Mesangium 
 Mesangial widening and nodules are due to increased synthesis of mesangial 
matrix(198) and decreased degradation secondary to cross- linking of glycosylated 
collagens .  Additional factors are considered in the section on pathogenesis. Dachs et 
al  noted that the first change consisted of widening of the usually delicate starnds of 
mesangial matrix with increase of the numbers of mesangial cells. The number of 
mesangial cells and cellular processes may be slightly increased within the expanded 
mesangial matrix.  These observations have been confirmed by morphometric 
analysis. Steffes et al  showed increase in volume fraction of mesangial matrix per 
glomerulus and in mesangial cells per glomerulus  in patients with type 1 diabetes 
compared with controls. The volume fraction of mesangium increases over the 
duration of the diabetes(34). In addition to occasional collagen fibrils, cell debris 
manifested as small calcific deposits, remnants of cell membranes, and scattered 
organelles are often present .  Some nodules develop loosening of the matrix, namely, 
mesangiolysis, resulting in detachment to endothelial cells and loss of the anchoring 
points of the GBM to the mesangium.  These alterations are thought to precede the 
exaggerated mesangial expansion of the single large nodules with laminated texture 
that are associated with microaneurysms. 
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 The major component of the increased matrix is type IV collagen .  Other 
components that are increased include type V and VI collagen, laminin, and 
fibronectin . Suzuki et al   examined glomerular and interstitial expression of the 
mRNAs of metalloproteinase-3, tissue inhibitor of metalloproteinase-1, and type IV 
collagen in diabetic nephropathy. These investigators found that the expression of 
these entities was inversely correlated with the degree of mesangial expansion but 
directly correlated with the severity of interstitial disease. Expression of integrins is 
increased  on all cell type in diabetic patients with moderate increase in mesangial 
matrix.  As mesangial matrix increases in parallel in mesangial cells, whereas it 
remains the same on epithelial cells with decreased expression in endothelial cells. 
The pathogenesis of increased matrix production is discussed in the section on 
pathogenesis. 
Hyalinosis 
 When the early hyalinosis or exudative lesion is observed with the electron 
microscope, it appears as a accumulation of homogeneous electron-dense  material 
between the endothelial cell and the GBM. As more material collects, it fills the 
capillary lumen.  On occasion, lipid droplets, cellular debris, or lipid- laden 
macrophages are present in association with these lesions. In obsolescent glomeruli, 
remains of the hyalinosis lesions formed earlier persist as denser areas within 
increased matrix and the GBM. Similar material may also be present within the 
mesangium.  One must distinguish such hyalinosis accumulations from immune 
deposits, although this distinction may be difficult. This material is identical to that 
seen in the subintima of arterioles with hyaline arteriolosclerosis. Furthermore, the 
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capsular drop is made up of similar material lying between Bowman’s capsule and the 
parietal epithelium. The pathogenesis of this lesion is not entirely clear. 
Clinicopathologic Correlations 
 The renal morphologic changes in diabetic nephropathy affect all four renal 
compartments, i.e., glomeruli, tubules, interstitium, and vessels. The changes in each 
of these four compartments encompass a spectrum of morphologic alterations 
showing good overall correlation with the biologic duration of the disease. Detailed 
morphometric studies, especially in patients with type 1 diabetes, have documented 
that some of the structural-morphologic changes, including both glomerular and 
tubulointerstital changes, show close correlation with the clinical-laboratory 
parameters of renal dysfunction. Studies addressing structural-functional correlation 
in patients with type 2 diabetes have demonstrated, in general, less precise correlation 
between morphologic findings and renal functional parameters that those seen in 
patients with type 1 diabetes. 
 The characteristic glomerular changes in diabetes include glomerular 
enlargement, diffuse thickening of the glomerular capillary basement membranes, 
mesangial expansion primarily owing to matrix accumulation, and progressive 
glomerulosclerosis with development of globally sclerotic glomeruli. One of the 
earliest and easiest morphologic changes to detect in diabetic nephropathy is the 
diffuse thickening of the glomerular capillary basement membranes (35). Precise 
quantitative measurements demonstrated that in patients with type 1 diabetes, 
thickening of proximal tubular basement membranes is strongly related to the 
thickening of the glomerular capillary basement membranes .  Although mesangial 
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matrix accumulation with mesangial expansion represents one of glomerulosclerosis, 
the increase in the mesangial fractional volume (i.e., the  volume fraction of the 
glomerulus occupied by mesangium (Vv[Mes/glom]) can be documented only  4 to 5 
years after the onset of diabetes in patients with type 1 diabetes(35). Once mesangial 
widening with matrix accumulation had developed in patients with type 1 diabetes, 
increases in the mesangial fractional volume (Vv [Mes/glom]) correlate precisely with 
the decrease in the peripheral glomerular capillary basement membrane filtration 
surface density .  Also, evidence for close relation between mesangial fractional 
volume (Vv [Mes/glom]) and urinary albumin excretion rate in patients with type 1 
diabetes has been provided in landmark studies involving elegant morphometric 
analyses by Maure et al  and Caromori et al .  Glomerular  fractional volume (Vv 
[Mes/glom])is also a strong concomitant of hypertension.  In patients with type 1 
diabetes, thickness(width) of the glomerular capillary basement membranes directly 
correlates with the blood pressure and the urinary albumin excretion rate; however, 
the correlation is weaker that the one seen with glomerular fractional volume(Vv 
[Mes/glom]).  The width of the glomerular capillary basement membranes is inversely 
correlated with the glomerular filtration rate (GFR)  whereas total peripheral capillary 
filtration surface is highly correlated with GFR in patients with type 1 diabetes.  In 
general, thickening of the glomerular capillary basement membranes and degree of 
mesangial expansion (i.e., glomerular fractional volume (Vv [Mes/glom]) increase in 
patients with type 1 diabetes from normoalbuminiuria to microalbuminuria to 
proteinuria; however, considerable overlap exists between these groups.  In addition, 
some normoalbuminuric patients with type 1 diabetes can have advanced glomerular 
lesions and other clinical finding of advancing renal disease such as low glomerular 
filtration rate and hypertension.  This is a indication that albuminuria, albeit a strong 
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predictor of progression, is still an imprecise indicator of diabetic nephropathy risk. 
Also, thought at one time to be part and parcel of diabetic nephropathy, glomerular 
capillary basement membrane thickening and mesangial expansion can progress at 
varying rates within and between patients with type 1 diabetes.  In some patients, 
marked glomerular capillary basement membrane thickening can be seen without 
significant increases in the mesangial fraci\tional volume (Vv [Mes/glom]) whereas 
others may show the opposite pattern. 
 Tubulointerstital changes in diabetic nephropathy include interstitial 
expansion owing to increase in cellular content and/or fibrosis, and tubular atrophy. 
Mild interstitial expansion in patients with long-standing type 1 diabetes is largely due 
to an increase in interstitial cell component that antedates interstitial fibrosis .  
Increased fractional volume of interstitial fibrillary collagen appears at later stages of 
the disease,when the glomerular filtration rate is already reduced .  This is different 
from the glomerular lesions in which mesangial matrix accumulation is the primary 
cause of mesangial widening even at the early stages of the disease. The 
extent/severity of interstitial fibrosis and global glomerulosclerosis have also been 
shown to correlate with the clinical manifestations of diabetic nephropathy in patients 
with type 1 diabetes (36,37). The extent of interstitial fibrosis has long been 
advocated as an independent predictor of chronic renal dysfunction as characterized 
by elevated serum creatinine not only in patients with diabetes including those with 
type 2 diabetes, but also in a number of various nondiabetic glomerular, 
tubulointerstital, and vascular diseases .  However, during the early stages of diabetic 
nephropathy, the extent of interstitial fibrosis as a predictor of renal dysfunction as 
characterized by changes in the GFR and/or microalbuminuria is of limited value. 
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 As already mentioned, the findings of studies addressing renal structural-
functional relationship in patients with type 2 diabetes are less conclusive than those 
in patients with type 2 diabetes are less conclusive that those in patients with type  
1 diabetes. In general patients with type 2 diabetes show greater morphologic 
heterogeneity of the renal lesions. This may, at least in part, be related to higher 
frequency of cardiovascular risk factors such as hypertension, hyperlipidemia, 
obesity, and accelerated arteriosclerosis in  patients  with type 2 diabetes. In a study of 
34 unselected patients (age: 58± 7years) with type 2 diabetes and micro albuminuria, 
renal biopsies revealed renal morphologic heterogentity with less than one third of 
patients having “Atypical” changes with absent or only mild diabetic glomerular 
lesions included tubulointerstital fibrosis with or without arteriolar hyalinosis and 
with or without global glomerulosclerosis. Some patients did not show any significant 
morphologic changes. The presence of both typical and a typical patterns of renal 
pathologic findings was associated indication that hyperglycemia may contribute to 
different patterns of renal injury in this patient populations..  In a study by Osterby et 
al , renal biopsies of 20 patients with type 2 diabetes showed similar morphologic 
changes to those seen in patients with type 1 diabetes, i.e., thickening of the 
glomerular capillary basement membranes and increased  mesangial volume ratios 
with mesangial matrix accumulation. However, the glomerular changes in this study 
were less advanced in patients with type 2 diabetes compared  with historical controls 
of patients with type 1 diabetes with similar degree of urinary albumin excretion. In 
addition, patients with type 2 diabetes had higher GFRs than patients with type 1 
diabetes with similar degree of urinary albumin excretion , possibly because of larger 
glomerular volumes in patients with type 2 diabetes, a progressive increase to the 
glomerular fractional volume(Vv[Mes/glom]) paralleled the clinical laboratory 
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presentation of diabetic renal disease from the normoalbuminiuria to 
microalbuminuria and overt nephropathy. 
 Numerical and structural abnormalities of the visceral epithelial cells 
(podocytes) have also been described in both type 1 and type 2 diabetic patients.   
A significantly decreased number of podocytes has been detected in both type 1 and 
type 2 diabetes. In patients with type 1 diabetes, widening of the foot processes of the 
visceral epithelial cells correlated with the urinary albumin excretion rate .  A 
significant inverse correlation between the number and density of podocytes per 
glomerulus and proteinuria has also been reported in patients with type 2 diabetes.  In 
pima Indians with type 2 diabetes the number or podocytes per glomerulus was the 
strongest predictor of progressive renal disease, with fewer cells predicting more rapid 
progression. Decreased glomerular expression of podocytes – associated nephrin, a 
protein known to have a significant role in maintaining normal permselectivity of the 
glomerular filtration barrier, has been described in patients with type 1 and type  
2 diabetes. Decreased in nephrin expression correlated with the broadening of the foot 
process width. One study indicated that reduction in nephrin expression was due to 
down-regulation of expression rather than decreased number of podocytes in the 
glomeruli. 
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MATERIALS AND METHODS 
 Type 1 diabetic patients attending kilpauk medical college outpatient 
department were enrolled in the study . These patients  were confirmed as type1 
diabetic by documenting low  c peptide level.  Height , weight, body mass index and 
smoking habits were recorded . Time of diagnosis of diabetes was enquired and the 
presenting symptom at the time of diagnosis was recorded.  The  duration of diabetes 
was calculated. All these patients were questioned for hospitalisation for any illness 
and for comorbid conditions. Requirement for insulin and their compliance to insulin 
were recorded. These patients were enquired for other drug intake and indigenous 
medicine intake. Pulse rate,  blood pressure and peripheral pulses were recorded. 
These patients were assessed for gastropathy, peripheral neuropathy and autonomic 
neuropathy. Electrocardiogram and for selected patients Echocardiography were also 
done. They were also examined for diabetic retinopathy by direct ophthalmoscopic 
evaluation and fluorescein angiography if necessary by ophthamologist.  Fasting lipid 
profile was done in these patients. Serum electrolytes like potassium, sodium, 
magnesium  and uric acid were measured. These patients were screened for viral 
markers like hepatitisB, hepatitis C and HIV. Ultrasonogram abdomen and KUB were 
done and kidney size was assessed.The urine was screened for proteinuria by 
sulfosalicilic acid method. Those who were negative for albuminuria were screened 
for microalbuminuria. Serum creatinine was measured on two consecutive days by 
jaffe’s method and the mean serum creatinine was calculated. Gfr was calculated by 
cock grauft and gault formula and those patients with a low gfr (less than 
90ml/min/1.73m2 were identified. Totally we had 37 patients with low gfr and 
normoalbuminuria( negative for microalbuminuria). These patients with low gfr by 
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cock grauft gault formula and negative for microalbuminuria (37patients)  were 
screened for gfr by DTPA scan. After doing radionuclide study (DTPA scan)  we had 
twenty patients with normoalbuminuria and negative for microalbuminuria and low 
gfr( less than 90ml/min) . These patients were subjected to renal biopsy after getting 
informed written consent. Renal biopsy was done as an outpatient proceedure and we 
had no complications. Two samples were taken and sent in formalin to renal 
pathologists for light microscopic studies.  Electron microscopic examination was not 
done due to unavailability.  Twenty patients with normoalbuminuria and normal gfr( 
>90ml/min by DTPA scan)  who were age and sex matched  with those with low gfr 
were registered as control. Duration of diabetes in the normal gfr and low gfr were 
compared. Serum magnesium level was compared between these two groups. 
Incidence of hypertension and retinopathy in both these groups were compared. The 
characteristic profile  of patients with low gfr was analysed with respect to duration of 
diabetes, serum magnesium level, hypertension, retinopathy and renal biopsy features. 
Stastical method like chi square and student t test were applied. 
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RESULTS 
 Total number of type1 diabetic patients screened in this study were 95.  
 Of which we selected  twenty patients with normoalbuminuria and low gfr by 
radionuclide scan. We compared these patients with age and sex matched twenty 
patients  with normoalbuminuria and normal gfr (>90ml/min by DTPA scan).  
Sex & age  distribution: 
 Both these groups were sex and age matched. 
 Duration of diabetes: 
 The duration of diabetes in patients with low gfr ranges from five years to 
twenty nine  years and  among patients with normal gfr it was three years to nine 
years .The mean duration of diabetes in low gfr group was twelve years and among 
normal gfr  it was five years.  This was stastically significant. 
Mean gfr: 
 The gfr in the low gfr group ranges from 25 to 89 and it was in the range of 92 
to 105 in normal gfr group. The mean gfr in low gfr group was 68  and in the normal 
gfr group it was 97.   
Serum magnesium: 
 The mean serum magnesium was  1.9 in the low gfr group and it was 2.4  in 
normal gfr group. This was  stastically significant with a p value of  less than .05 
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Hypertension & retinopathy: 
 Hypertension was seen in five patients (25%)  in the low gfr group and it was 
seen only in one patient (5%)  in the normal gfr group. Retinopathy was seen in eight 
patients (40%)  in the low gfr group and only in one patient (5%)  in the normal gfr 
group. This was found to be stastically significant with a p value of less than .05  . 
Renal biopsy: 
 Renal biopsy was done in all the twenty patients in low gfr group of which 
fourteen patients showed characteristic diabetic changes of diffuse glomerulosclerosis 
and no other cause could be ascribed for low gfr  and three patients showed nodular 
sclerosis along with diffuse changes. Three patients showed atypical pattern with 
predominant tubulointerstitial involvement with tubular atrophy, interstitial fibrosis 
and arteriolar hyalinosis. 
Charesteristics of the patients with normoalbuminuric diabetic nephropathy: 
 We had seventeen patients with renal biopsy proven normoalbuminuric 
diabetic nephropathy. 
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Age & sex distribution: 
Age No. P - value 
< 20 2 
0.000 20 - 40 11 
> 40 4 
 
 
 Of the seventeen patients eight (47%) were male and the age ranges from 19 to 
47 years  with a mean age of 33 years. Two patients were below 20years of age and 
eleven patients were between 20 to 40 years and four patients were more than 40 
years. 
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Gender No. P - value 
Male 8 
0.000 
Female 9 
 
 
Gfr: 
 Thirteen patients (76%) had gfr of less than 75 and 4(24%)  patients had gfr of 
more than 75. The mean gfr was found to be 67ml/min.     
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GFR No. P - value 
< 75 13 
0.000 
> 75 4 
 
 
Duration of diabetes: 
 Nine patients had a diabetic duration of less than ten years and eight patients 
had a duration of more than ten years. The mean duration of diabetes in this study 
group was found to be 11years . 
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Duration No. P - value 
< 10 9 
0.000 
> 10 8 
 
 
 
Serum magnesium: 
 Eleven patients (65%) had a serum magnesium of less than 2mg/l and only six 
patients had serum magnesium of more than 2 mg/dl. 
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Magnesium No. P - value 
< 2 11 
0.000 
> 2 6 
 
 
Hypertension & retinopathy: 
 Among the seventeen patients five patients (29%)  had hypertension and eight 
patients (47%)  had diabetic retinopathy changes. 
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Hypertension No. P - value 
Yes 5 
0.020 
No 12 
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Retinopathy No. P - value 
Yes 8 
0.002 
No 9 
 
 
Comparing Duration of diabetes  with hypertension & retinopathy: 
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 Comparison of duration with Hypertension 
Duration 
Hypertension 
P - Value 
Yes No 
< 10 0 12 
0.000 
> 10 5 3 
 
Comparison of duration with Magnesium 
Duration 
Magnesium P – 
Value < 2 > 2 
< 10 8 4 
0.858 
> 10 5 3 
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Comparison of duration with Retinopathy 
Duration 
Retinopathy 
P - Value 
Yes No 
< 10 1 11 
0.000 
> 10 7 1 
 
Comparison of duration with Renal biopsy charecteristic of diabetic 
nephropathy 
Duration 
Renal biopsy 
P – Value 
Yes No 
< 10 9 3 
0.139 
> 10 8 0 
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Comparison of GFR with Hypertension  
GFR 
Hypertension 
P - Value 
Yes No 
< 90ml 5 15 
0.080 
> 90ml 1 19 
 
Comparison of GFR with magnesium 
Magnesium N Mean Std. Deviation 
Std. 
Error 
Mean 
P - Value 
< 2 20 1.9950 .24382 .05452 
0.000 
> 2 20 2.4750 .40246 .08999 
 
Comparison of GFR with Retinopathy 
GFR 
Retinopathy 
P - Value 
Yes No 
< 90ml 8 12 
0.007 
> 90ml 1 19 
 
 Among eight patients with a duration of diabetes more than ten years  five had 
hypertension and seven patients had diabetic retinopathy changes. This was stastically 
significant.                                          
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DISCUSSION 
 Long standing type1 diabetic patients with normal albumin excretion rate are 
still at risk of developing clinically significant nephropathy. It is therefore important 
to identify markers of increased nephropathy risk among these patients. One 
possibility is to perform kidney biopsy in such patients. However this is not very 
practical in most clinical settings. Thus we examined whether reduced gfr can be 
predictive of more advanced underlying glomerular lesions. It was  first  reported that 
reduced gfr in eight normoalbuminuric longstanding type1 diabetic women was 
associated with worse diabetic glomerular lesions. Shortly thereafter, a small group of 
normoalbuminuric  long standing type1 and type2 diabetic largely female patients 
with reduced gfr was described. A similar prevalence of reduced gfr was reported 
among longstanding normoalbuminuric and normotensive  type1 diabetic patients in 
brazil. However many other investigators did not encounter reduced gfr in 
normoalbuminuric type1 diabetic patients.  
 The existence of normoalbuminuric diabetic kidney disease was demonstrated 
in the  united kingdom prospective diabetes study ( UKPDS).  In this cohort study 
they followed 4000 diabeteic patients with normoalbuminuria and  normal creatinine 
clearance as estimated by cockcroft-gault formula. They followed them for a median 
of about 15 years. In this about 12% of patients with microalbuminuria manifested 
with a decreased creatinine clearance first. Of those patients with decreased creatinine 
clearance  about 51% never had albuminuria at all. This existence of 
normoalbuminuric kidney disease  has been replicated also in NHANES as well as in 
multiple cohort studies in australia , in japan and in italy.there are also multiple cohort 
studies in type 1 diabetes also showing the same.  In this cohort there were 105 
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patients with type1 diabetes who had no albuminuria, and they underwent  gfr 
measurement with iothalamate clearance, and they found that 23 of those 105 patients 
had a decreased gfr less than 90. There were also more prevalence  of hypertension 
and retinopathy in the group with low gfr. On renal biopsy they found typical diabetic 
nephropathy changes on histology  in low gfr group. The basement membrane width 
was increased and  fractional mesangial matrix and mesangium per glomerulus was 
expanded in those with decreased gfr                
 In our study we analysed 95 type1 diabetic patients.  45 were female and 50 
were male. Most of them were in the age group of 20-40yrs with a mean duration of 
less than 10yrs in 60 patients and more than 10yrs in 35 patients. In this study the 
mean gfr was low in  female comparing to  male and in  those patients with long 
duration of diabetes (more than 10yrs). In this study we compared the 20 patients with 
low gfr and 20 patients with normal gfr. The sample size is small as we did study in 
type1 diabetic patients.  There was no significant sex and age difference between 
these two groups as the patient selection was done by matching these parameters. The 
mean gfr was found to be 68ml/min in  low gfr group  and it was 97ml/min in the 
normal gfr group.  
 The duration of diabetes in the low gfr group is 12yrs and it is 5 years in 
normal gfr group. This data is highly significant and this emphasize the fact that the 
incidence of normoalbuminuric diabetic nephropathy increases as duration of diabetes 
increases. This is same as we see in albuminuric diabetic nephropathy.   
 The mean serum magnesium is 1.9 in patients with low gfr and it is 2.4 in 
normal gfr group. This is statistically significant. There are many studies showing that 
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lower magnesium level in diabetic patients are associated with increased incidence of 
comorbid illness (38,39,40). If this is proved right  then these patients with low gfr are 
more prone for diabetic end organ complications. 
 Hypertension is seen in 5 patients with low gfr while it is seen in only one 
patient with normal gfr . Similarly retinopathy is seen in 8 patients with low gfr while 
it is seen in only one patient with normal gfr.  These data are statistically significant. 
This confirms the fact that these patients with low gfr are placed in a high risk zone 
comparing to those with normal gfr. Generally there are  heterogeneity in renal biopsy 
in diabetics.  There are three categories identified .  category 1- normal or near normal 
structure, just a mild amount of mesangial expansion. Category2- thickening of 
basement membrane, arteriolar hyalinosis and nodular mesangial expansion. 
Category3- atypical patterns of renal injury with more tubulointerstitial disease where 
the tubular basement membrane was thickened and that there was more tubular 
atrophy, a lot more interstitial fibrosis and much greater arteriolar hyalinosis(41).                    
 In a study by nosadini, they looked at a large cohort of patients in italy. They 
followed them  from the initial diagnosis of diabetes until they got to a gfr estimated 
with creatinine of about 60-75. Then , they made sure that that was actually their gfr 
measuring it with isotope labelled creatinine EDTA. They found that 30 of these 
patients had albuminuria and 27, again, had normal albuminuria. Then they went on to 
biopsy them. Interestingly , 93% of the patients who had albuminuria had the typical 
diabetic histopathology whereas only about 20% with normal albuminuria had this 
pathology. It was more often those with normal albuminuria who fell into category3. 
Very few of those with albuminuria exhibited this category. So they assumed that it is 
the difference in histology that accounts  for this existence of normoalbuminuric 
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diabetic kidney disease and that infact this may be reflective of more the vascular 
outcomes in diabetes rather than the specific glomerular diabetic nephropathy that we 
always assume patients to have(42). In this study we did renal biopsy to those twenty 
patients with low gfr and we found that seventeen patients had typical diabetic 
nephropathy changes. Only three patients we had the histology showing predominant 
tubulointerstitial changes. So we have this data paradoxical to this Italian study.  
 When we analysed the 17 patients with typical diabetic nephropathy changes  
we could not find any statistically significant change with respcct to gender. Among 
them 13 patients had gfr less than 75ml/min. As we had 5 patients with hypertension 
among these seventeen patients,  the incidence of hypertension among these 
normoalbuminuric diabetic nephropathy from our study is 35%. Similarly we had 8 
patients with retinopathy in this group accounting for an incidence of 48%. So there is 
an increased incidence of hypertension and retinopathy in this normoalbuminuric 
diabetic nephropathy population. 
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CONCLUSION 
1. There exists an entity – normoalbuminuric diabetic nephropathy in type1 
diabetic patients 
2. Incidence of normoalbuminuric diabetic nephropathy increases with duration 
of diabetes. 
3. There is an increase incidence of hypertension(29%) and retinopathy(47%) 
in this group of patients. 
4.  Serum magnesium is low in these patients with normoalbuminuric diabetic 
nephropathy the significance of which is not clearly known yet there are 
studies to say that low magnesium is associated with poor outcome. 
5. So along with screening for albuminuria periodic screening for GFR should 
also be done so that these normoalbuminuric diabetic nephropathy can be 
detected early. This patients should be treated as high risk and they should 
avoid radiocontrast and other nephrotoxic drugs if not mandatory.  
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gfr<90ml  s.no male female age gfr
duration of 
diabetes     hypertension magnesium retinopathy renal biopsy
1 yes 18 89 5 no 2.1 no yes
2 yes 47 73 2 no 2 no yes
3 yes 15 66 6 no 2.2 no yes
4 yes 41 79 18 yes 1.9 yes yes
5 yes 15 82 7 no 1.8 no no
6 yes 29 25 2 no 2 no yes
7 yes 35 64 11 yes 2.1 yes yes
8 yes 53 57 29 yes 1.7 yes yes
9 yes 28 88 1 no 2 no yes
10 yes 25 64 3 no 1.6 no yes
11 yes 24 46 10 no 2 yes yes
12 yes 22 64 4 no 2.1 no no
13 yes 35 81 12 yes 2.8 no yes
14 yes 39 71 13 no 2.1 yes yes
15 yes 25 52 2 no 2 no no
16 yes 27 62 5 no 1.8 no yes
17 yes 38 65 18 yes 1.9 yes yes
18 yes 39 65 23 no 1.8 yes yes
19 yes 28 67 11 no 1.9 yes yes
20 yes 42 60 9 no 2.1 no yes
MASTER CHART - 2 
gfr<90ml s.no male female age gfr
duration of
diabetes     hypertension magnesium retinopathy renal biopsy
1 yes 18 89 5 no 2.1 no yes
2 yes 47 73 2 no 2 no yes
3 yes 15 66 6 no 2.2 no yes
4 yes 41 79 18 yes 1.9 yes yes
5 yes 15 82 7 no 1.8 no no
6 yes 29 25 2 no 2 no yes
7 yes 35 64 11 yes 2.1 yes yes
8 yes 53 57 29 yes 1.7 yes yes
9 yes 28 88 1 no 2 no yes
10 yes 25 64 3 no 1.6 no yes
11 yes 24 46 10 no 2 yes yes
12 yes 22 64 4 no 2.1 no no
13 yes 35 81 12 yes 2.8 no yes
14 yes 39 71 13 no 2.1 yes yes
15 yes 25 52 2 no 2 no no
16 yes 27 62 5 no 1.8 no yes
17 yes 38 65 18 yes 1.9 yes yes
18 yes 39 65 23 no 1.8 yes yes
19 yes 28 67 11 no 1.9 yes yes
20 yes 42 60 9 no 2.1 no yes
MASTER CHART - 2
gfr>90ml s.no male female age gfr duration of diabetes      hypertension      magnesium      retinopathy      renal biopsy
1 yes 20 98 5 no 2.2 no
2 yes 45 92 3 no 2.4 no
3 yes 15 96 4 no 2.5 no
4 yes 41 99 7 no 2.7 no
5 yes 17 95 6 no 1.8 no
6 yes 29 102 9 no 1.4 no
7 yes 35 105 3 no 1.9 no
8 yes 55 97 2 no 2.7 no
9 yes 26 95 5 no 2.9 no
10 yes 22 99 8 no 2.5 no
11 yes 26 98 6 no 2.7 no
12 yes 24 93 9 no 2.2 no
13 yes 37 98 4 no 2.8 no
14 yes 24 100 3 yes 2.7 yes
15 yes 28 104 7 no 2.9 no
16 yes 27 97 3 no 2.8 no
17 yes 30 98 2 no 2.7 no
18 yes 39 96 3 no 2.8 no
19 yes 30 95 4 no 2.6 no
20 yes 41 92 6 no 2.3 no
MASTER CHART. 1
